N Neymark
N Neymark
This article first discusses at what level of clinical decision making cost considerations may be most pertinent and important. It is argued that cost assessments will be of most relevance and value at an intermediate level of clinical deci...
On the road towards better health gain through co-operation in the European Union? [0.03%]
欧盟合作促进健康之路——更好的成效吗？
K Schutyser
K Schutyser
Explained are some 4 paradoxes, amongst many others, in healthcare and hospital policy and the turbulent "changes" and so-called changes they are going through all over Europe:--change vs being changed?--cost vs investment?--compete vs co-o...
Induction and adjuvant chemotherapy for head and neck cancer: future perspectives [0.03%]
头颈部肿瘤的诱导及辅助化疗：未来展望
A A Forastiere
A A Forastiere
Induction and adjuvant chemotherapy have been studied in combined modality trials over the last two decades. Induction chemotherapy as a strategy has failed to improve survival or local-regional control although some studies have reported a...
Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life [0.03%]
适形及调强放射治疗头颈部肿瘤：提高目标照射量、唾液腺功能和生活质量的潜力
A Eisbruch,L A Dawson,H M Kim et al.
A Eisbruch et al.
Purpose: To develop techniques which facilitate sparing of the major salivary glands while adequately treating the targets in patients requiring comprehensive bilateral neck irradiation (RT). ...
Postoperative radiotherapy of paranasal sinus tumours: a challenge for intensity modulated radiotherapy [0.03%]
鼻窦肿瘤术后放射治疗的强度模体放疗面临的挑战
F Claus,L Vakaet,W De Gersem et al.
F Claus et al.
Background and purpose: Intensity modulated radiotherapy (IMRT) is used in our department for treatment of paranasal sinuses. We describe the methodology that was developed together with the clinical implementation, illus...
Case Reports
Acta oto-rhino-laryngologica Belgica. 1999;53(3):263-9. DOI: 1999
M J de Jonge
M J de Jonge
Chemotherapy plays a definite role in the management of head and neck cancer. Several new agents have been introduced recently. The following are reviewed briefly: gemcitabine, edatexate, MTA, vinorelbine and topoisomerase I inhibitors.
A A Forastiere
A A Forastiere
The taxoids docetaxel and paclitaxel entered into clinical trials in the 1980s. Paclitaxel has dominated clinical investigations in the United States while docetaxel gained a foothold early in Europe. Now both agents are under intensive stu...
P H De Mulder
P H De Mulder
Chemotherapy in head and neck cancer can be given in metastatic disease at presentation, in locally far advanced disease not amendable for curative treatment with surgery and/or radiotherapy, in the neo-adjuvant setting, in recurrent diseas...
M E Sebelik,H Shami,K T Robbins
M E Sebelik